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Abstract
Factor V Leiden mutation and pregnancy
Haemostasis during pregnancy in non-carriers and carriers of factor V Leiden mutation, 
with special emphasis on placenta-mediated and venous thromboembolic complications 
and on blood coagulation and ﬁbrinolysis markers for prediction of complications.
Factor V Leiden (FVL) mutation elevates the risk of venous thromboembolism 
(VTE) in general. During pregnancy, the haemostatic balance is changed in the 
direction of hypercoagulability, resulting in an increased incidence of VTE. 
42 women were followed longitudinally during pregnancy and the puerperium. 
Classic and modiﬁed activated protein C (APC) ratios decreased during pregnancy. 
However, the modiﬁed ratio was above the lower limit for non-carriers, and can be 
used to detect the FVL mutation during pregnancy. Increased levels of prothrombin 
fragment 1+2 (F1+2), soluble ﬁbrin (SF) and D-dimer indicated activation of blood 
coagulation. Fibrinogen, Factor VIII and plasminogen activator inhibitor type 1 
and type 2 levels increased. Free protein S and tissue plasminogen activator activity 
decreased. Protein C levels remained unchanged. Sonoclot analyses indicated hy-
percoagulability during pregnancy. The same reference Sonoclot curve can be used 
throughout pregnancy.
5 986 women were genotyped for the FVL mutation; the prevalence of FVL car-
riership was 8.1%. 500 carriers and 1 058 controls were followed longitudinally and 
haemostatic markers were analysed. There were no diﬀerences regarding placenta-
mediated complications or gestational age at delivery. The incidences of neonatal as-
phyxia, eclampsia, intrauterine fetal death, intrapartum death and unexplained late 
miscarriage were low. The incidence of blood loss exceeding 1000 ml at delivery was 
lower in FVL carriers. There were three VTEs among FVL carriers and none among 
controls. No diﬀerence in superﬁcial thrombophlebitis was found. Genotyping for 
the FVL mutation in healthy pregnant women without heredity for VTE is doubt-
ful, nor can genotyping be justiﬁed in women with obstetric complications. 
F1+2 and D-dimer increased during pregnancy and levels were higher than eight 
weeks postpartum. Alterations in SF were minor or absent. Levels of F1+2 and SF 
in carriers and non-carriers were the same during pregnancy. Carriers had higher 
levels of D-dimer than non-carriers during both pregnancy and the puerperium. 
The levels of all markers were in the same ranges in women with and without com-
plications, and were unaﬀected by zygosity or additional thrombophilia. F1+2, SF 
or D-dimer cannot serve as predictors of placenta-mediated complications or VTE 
in FVL carriers.
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Abbreviations
Abbreviations
APC   activated protein C
APTT   activated thromboplastin time
AT   antithrombin
BMI   body mass index
CI   conﬁdence interval
DIC   disseminated intravascular coagulation 
DVT   deep vein thrombosis
ELISA   enzyme-linked immunosorbent assay 
F 1+2   prothrombin fragments 1+2
F   factor; a following the respective factor means activated
FVL   Factor V Leiden
Hb   haemoglobin concentration
HELLP  syndrome of haemolysis, elevated liver enzymes and low platelets
IUFD   intrauterine fetal death
IUGR   intrauterine growth retardation
LA   lupus anticoagulants
LGA   large for gestational age
LMWH  low molecular weight heparin
MP  mild and moderate preeclampsia
OAC   oral anticoagulants
OR   odds ratio
p1   one-sided p-value
p2   two-sided p-value
PAI-l   plasminogen activator inhibitor type 1
PAI-2   plasminogen activator inhibitor type 2
PCR   polymerase chain reaction
PE   pulmonary embolism
r   Pearson’s correlation coeﬃcient 
rs   Spearman correlation coeﬃcient 
s-CT   spiral computed tomography
SD   standard deviation
SF   soluble ﬁbrin
SGA   small for gestational age
SP   severe preeclampsia
TAFI   thrombin-activated ﬁbrinolytic inhibitor 
TF   tissue factor
TFPI   tissue factor pathway inhibitor
t-PA   tissue plasminogen activator
u-PA   urokinase plasminogen activator
VTE   venous thromboembolism
vWF   von Willebrand factor 
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De?nitions
Definitions
Blood loss: 
Routinely estimated and registered by the midwife at delivery 
Blood pressure: 
Measured in the sitting subject’s left arm at heart level after a 20-minute rest
Chronic hypertension: 
≥ 90 mm Hg diastolic blood pressure before 20 weeks of gestation or ongoing anti-
hypertensive medication
Double heterozygosity: 
Heterozygosity for both Factor V Leiden (FVL) mutation and the prothrombin 
G20210A gene mutation
Birth weight deviation: 
100* mean value of ((weight – mean weight for the same gestational age and gender)/ 
(mean weight for the same gestational age and gender)). Gender-speciﬁc intrauterine 
growth curves based on ultrasonically estimated fetal weights were used for com-
parison (Maršál et al 1996)
Gestational hypertension: 
≥ 90 mm Hg diastolic blood pressure on two occasions at minimum 6 hours interval 
after gestational week 20
HELLP syndrome: 
Classiﬁed according to Martin et al, i.e. epigastric pain, haemolysis, elevated se-
rum alanine aminotransferase and thrombocytopenia with or without other signs of 
preeclampsia (Martin et al 1990)
LGA: 
Birth weight exceeding two standard deviations (SD) (Maršál et al 1996)
Mild preeclampsia: 
≥ 90 mm Hg diastolic blood pressure on two occasions 
proteinuria (≥ 1+ reading on dipstick) on two occasions at minimum 6 hours interval 
and negative urine culture
Neonatal asphyxia: 
Apgar score <7 at 5 and 10 minutes
Severe preeclampsia: 
As mild preeclampsia but with one of the following additional ﬁndings:
≥ 120 mm Hg diastolic blood pressure once or ≥ 110 mm Hg diastolic blood pressure 
on two occasions at minimum 6 hours interval 
proteinuria ≥ 3g per 24 hours 
symptoms/signs of organ failure such as renal insuﬃciency, pulmonary oedema, 
eclampsia, visual disturbances, intrauterine growth retardation (IUGR) or platelet 
count ? 100 x 109/L
SGA: 
Birth weight below two SD (Maršál et al 1996) 
Superﬁcial thrombophlebitis: 
Palpable, tender vessel accompanied by a surrounding area of localized inﬂammation
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Placental abruption: 
Abdominal pain, uterine tenderness, frequent small contractions and elevated uter-
ine tone, together with vaginal bleeding or a retroplacental clot, i.e. a condition 
leading to immediate delivery
Placenta-mediated complications: 
Generic term for preeclampsia, IUGR and placental abruption 
VTE: 
Venous thromboembolism including deep venous thrombosis (DVT)?and pulmonary 
emboli?????
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Background
General aspects of haemostasis
The haemostatic system (Figure 1) is designed to maintain blood in a ﬂuid state 
under physiological conditions, but is primed to react explosively to vascular injury 
in order to stem blood loss by sealing the defect in the vessel wall. Normal vascular 
endothelium maintains blood ﬂuidity by inhibiting blood coagulation and platelet 
aggregation and promoting ﬁbrinolysis. After the vessel is injured, blood is exposed 
to components from the deeper layer of the vessel wall, including adhesive proteins 
like collagen, ﬁbronectin, laminin, vitronectin, and von Willebrand factor (vWF), 
that promote platelet adhesion, and tissue factor, that triggers blood coagulation. 
Primary haemostasis is a series of events including vasoconstriction and platelet acti-
vation. Vasoconstriction diverts blood from the site of the injury and protects it from 
exposure to subendothelial structures that activate blood coagulation. Platelets ad-
here to the injured vessel wall, a process mediated by glucoprotein Ib which binds to 
vWF on the endothelial cells. In addition, activation of platelets leads to a change in 
shape, leading to exposure of new receptors on the platelet membrane which makes 
the platelets able to form aggregates, mediated by the bridging of glucoprotein IIb 
IIIa to glucoprotein IIb IIIa on another platelet by ﬁbrinogen. This primary platelet 
plug is very fragile and must, in order to avoid detachment and subsequent resumed 
bleeding, be stabilised and more ﬁrmly anchored to the vessel wall; this is achieved 
via ﬁbrin formation by the coagulation pathway also called secondary haemostasis. 
Secondary haemostasis is a chain reaction involving proteolytic enzymes, the coagu-
lation factors (F), present in circulating blood as inert proenzymes. Before partici-
pating in the coagulation pathway, they are activated by proteolytic cleavage after 
binding to speciﬁc protein cofactors on phospholipid surfaces. FVII, present in the 
circulation in its active form in trace amounts, is one exception. Tissue factor (TF), a 
membrane protein in adventitial ﬁbroblasts, binds to FVIIa, one of the soluble clot-
ting factors, with high aﬃnity and this complex initiates the blood clotting cascade. 
The complex between TF and FVIIa activates FX into FXa, which in turn, together 
with its cofactor FVa, activates prothrombin into thrombin (FIIa) ( the initial phase 
of the blood coagulation or TF pathway). This complex also activates FIX. Throm-
bin binds to phospholipid surfaces of the platelets, if protein Z is present, and acts on 
many substrates, resulting in increased formation of thrombin, i.e. the “ampliﬁca-
tion phase of coagulation” or the “thrombin burst”. Thrombin activates FV, FVIII, 
FXI and FXIII as well as platelets and stimulates platelet secretion. FVIIIa activates 
FXI which in turn activates FIX. FVIIIa is also a co-factor of FIXa and together they 
form the “tenase” complex, which activates FX; the cycle continues and more and 
more thrombin is formed. Thrombin’s primary role is the conversion of ﬁbrinogen 
to ﬁbrin, the main component of a haemostatic plug. The conversion of prothrombin 
to thrombin and the activation of FX take place on the platelet membrane surface. 
The ﬁnal step is the cross-linking of ﬁbrin by FXIIIa. The ﬁrm platelet-ﬁbrin clot 
subsequently retracts, a process that is also platelet-dependent. Thrombin occupies a 
central role in the process of haemostatic plug formation, inﬂuencing its shape, rate 
of formation and size.
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If no systems regulated this process, all circulating blood would coagulate in a cou-
ple of minutes. Antithrombin (AT) is the most important physiological inhibitor of 
thrombin and other activated serine proteinases of the coagulation system in cir-
culating blood, TF-FVIIa complex, FIXa, FXa and FXIIa. The created thrombin 
is modulated by reacting with thrombomodulin on intact endothelium cells close 
to the injury. This restructured thrombin activates protein C, another important 
inhibitor of blood coagulation, a reaction augmented by endothelial cell protein C 
receptor. APC’s task is to terminate surplus thrombin generation by inactivating 
FVa and FVIIIa. Free protein S and FV act as cofactors to APC in its inactivation 
of FVIIIa. In this reaction, the FV molecule is cleaved by APC at both Arg306 and 
Arg506. The cleavage at Arg506 is important for the ability of FV to serve as a cofac-
tor. Protein S, in its free form, also acts as a cofactor for APC in the inactivation of 
FVa. In this inactivation reaction, cleavage at Arg506 is fast but results only in partial 
inactivation while cleavage at Arg306 is slow but results in substantial inactivation.
The active forms of most serine proteases in the clotting system, except FVIIa, have 
extremely short plasma half-lives (measured in seconds) because plasma contains 
high concentrations of protease inhibitors. Activated FXa and the TF-FVIIa com-
plex are inhibited by tissue factor pathway inhibitor (TFPI). FXa is inhibited by Z 
protease inhibitor, a reaction enhanced by protein Z. 
Simultaneously with the onset of ﬁbrin formation, the clot starts to dissolve, a pro-
cess called ﬁbrinolysis. Endothelial cells liberate tissue plasmin activator (t-PA) after 
stimulation by thrombin, ﬁrmly bound to ﬁbrin.  Fibrin serves as a cofactor enabling 
eﬃcient activation of plasminogen to plasmin by t-PA. Plasminogen also binds to 
ﬁbrin; the substrate ﬁbrin is thus the site of both the activator and the proenzyme. 
Plasmin cleaves both ﬁbrinogen and ﬁbrin to produce degradation products which 
inhibit thrombin action and ﬁbrin polymerisation, serving as natural anticoagu-
lants. It also exerts positive feedback by cleavage of plasminogen, rendering it more 
susceptible to activation. Fibrinolysis is subject to multiple regulatory mechanisms. 
The main inhibitors of ﬁbrinolysis are plasminogen activator inhibitor (PAI)-1, ?2-
antiplasmin, lipoprotein (a) and thrombin-activated ﬁbrinolytic inhibitor (TAFI). 
FXIIIa-induced cross-linking of the ﬁbrin matrix renders it much more resistant 
to plasmin action. Many other elements, both in circulating blood and membrane-
bound in the endothelial cells, enhance or impair haemostasis. All components in 
the haemostatic system must be intact and balanced in order to avoid VTE events or 
abnormal bleeding. Furthermore, platelets are fundamental components of haemo-
stasis and their action is aﬀected by both activators and inhibitors.
17
Back ground
Vessel damage
Tissue factor
FVIIa FVII
FXl FXla
FlX *FIXa
FVlll FVllla FVIIIia
Protein S
Heparin FX FXa FXia APC
FV FVa ** FVia
Protein C Activated protein C (APC)
Prothrombin Thrombin
Antithrombin
At site of injury On intact endothelium
(-) 
Fibrinogen Fibrin
Plasminogen
PAI-1
PAI-2 (-) (+) t-PA
TAFI
2-antiplasmin
Plasmin
Degradation products
D-dimer
* Tenase complex, ** Prothrombinase complex, a: activated, ia: inactivated
Thrombomodulin
Procoagulation
Anticoagulation
Figure 1.  Coagulation, anticoagulation and ﬁbrinolysis.
Sonoclot analysis
The Sonoclot® analyser presents a global analysis of a patient’s tendency to bleed 
or clot in less than 15 minutes. The method assesses all the diﬀerent parts of hae-
mostasis with the exception of endothelial action. Routine coagulation workup is 
more time-consuming and only provides information about the diﬀerent steps in 
haemostasis. Some haemostatic tests, such as platelet function tests and ﬁbrinolysis 
analyses, are not available as rapid tests and bleeding time can be diﬃcult to analyse. 
Activated thromboplastin time (APTT) and prothrombin time measure the inter-
val from the ﬁrst steps in the coagulation cascade until ﬁbrin formation starts. The 
Sonoclot® analyser, on the other hand, provides information about the velocity of 
total ﬁbrin formation, ﬁbrin polymerisation and ﬁbrinolysis (Hett et al 1995), and 
imitates haemostasis in vivo. It was invented in order to meet the demand for rapid 
haemostatic assessments during coronary artery bypass surgery (Tuman et al 1989). 
Blood is analysed bedside and the device can easily be moved together with the pa-
tient between the antenatal ward, delivery ward, operating theatre and intensive care 
α
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unit. Coagulation status is assessed in whole blood, allowing in vivo coagulation 
system interactions with platelets and red blood cells, providing useful information 
on platelet function. 
The following variables are analysed in a Sonoclot curve: sonact time, clot rate, sec-
ondary rate, peak amplitude, peak time and downward rate. The sonact time is the 
time from coagulation activation until ﬁbrin formation starts. The clot rate reﬂects 
the rate of ﬁbrin formation. The secondary rate reﬂects platelet interaction with 
formed ﬁbrin. The peak time reﬂects platelet number and function. The peak am-
plitude depends on platelet number and ﬁbrinogen concentration as well as on the 
degree to which the cuvette is ﬁlled, the degree of rouleau formation and the haema-
tocrit. The downward rate reﬂects both clot retraction and ﬁbrinolysis. 
Sonoclot analysis is considered to be a valuable complement to an ordinary routine 
coagulation workup (Saleem et al 1983) and has been found to be a better predictor 
of postoperative haemorrhage than ordinary haemostatic analyses and useful in the 
process of individualising and optimising the use of blood components and haemo-
static drugs (Ekbäck et al 1995, Saleem et al 1983, Stern et al 1989, Tuman et al 
1989). The beneﬁts of the Sonoclot®  analyser have been documented  in connection 
with liver transplantation (Chapin et al 1989), hip and knee surgery (Ekbäck et al 
1995, Schött et al 1995), neonatal care (Blifeld et al 1986, Yang et al 1995), treat-
ment of DIC in sepsis with plasmapheresis (Schött et al 1995) and the determina-
tion of hypercoagulability (Amirkhosravi et al 1996, Francis et al 1994, Peck 1979, 
Perkash et al 1993, Pivalizza et al 1997, Spillert and Lazaro 1987, Sugiura et al 1982). 
The Sonoclot® analyser might be useful in managing obstetric haemostatic compli-
cations. Very few studies have been published concerning its use during pregnancy 
(Goldstein 1989, Liszka-Hackzell and Schött 2004, Steer 1993, Steer and Krantz 
1993). Reference intervals for the Sonoclot variables in pregnant women are as yet 
unknown. 
Haemostasis during pregnancy and postpartum 
During pregnancy the haemostatic balance changes in the direction of hypercoagu-
lability, thus decreasing the risk of bleeding complications in connection with de-
livery, but also raising the risk of thromboembolic complications. Platelet activation 
increases and the platelet count may decrease moderately during the third trimester 
as a result of increased platelet consumption in the uteroplacental unit. The concen-
trations of FV, FVII, FVIII, FIX, FX, FXII, vWF and ﬁbrinogen increase. The in-
hibition of blood coagulation is decreased by decreased levels of protein C inhibitor 
and free protein S. However, the increased levels of TFPI inhibit the enhancement 
phase by inactivating FXa. The levels of AT and protein C remained unchanged. 
The PAI-1 level is increased, mainly due to secretion from the endothelial cells in the 
placenta, and the basal activity of t-PA is decreased (Ishii et al 1994), but the mean 
velocity of clot lysis in the euglobulin clot lysis test does not diﬀer from that in non-
pregnant adults, suggesting that the ﬁbrinolytic system remains active and compen-
sates for increased ﬁbrin formation (Smith et al 2003). D-dimer levels thus increase, 
reaching maximum levels after delivery. Fibrinolytic activity probably occurs pri-
marily in the systemic circulation, while ﬁbrinolysis in the placenta is depressed due 
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to increased secretion of PAI-1. PAI-2, secreted by the placenta, aﬀects the systemic 
ﬁbrinolysis process to a lesser extent. It does not inhibit single-chain t-PA and its 
eﬀect on two-chain t-PA is 100-fold weaker than that of PAI-1. The more eﬃcient 
inhibition by PAI-2 of urokinase plasminogen activator (u-PA) than of t-PA suggests 
that its primary role may be in regulating extracellular u-PA, for instance during 
growth and remodelling of the placenta (Thorsen et al 1998).
 
Markers of blood coagulation activation and ?brinolysis
Ongoing blood coagulation and ﬁbrinolysis can be measured by diﬀerent mark-
ers of blood coagulation activation, ﬁbrin formation and ﬁbrin degradation. After 
activation of the blood coagulation system, prothrombin is converted to thrombin 
by the splitting of the prothrombin fragments F1+2 (F1+2). The resulting enzyme, 
thrombin, is rapidly inactivated by AT, forming the thrombin-antithrombin com-
plex. Quantiﬁcation of F1+2 makes it possible to monitor even a minor degree of 
blood coagulation activation. Only one type of assay for F1+2, the Enzygnost F1+2, 
is commercially available. This is an enzyme immunoassay for the in vitro determi-
nation of human F1+2 and is based on the sandwich principle. 
Free thrombin cleaves ﬁbrinogen to ﬁbrin monomer in a multi-step process that 
proceeds via a series of intermediate products. At an early stage of ﬁbrin formation, 
soluble ﬁbrin (SF) complexes are formed between ﬁbrin monomers and ﬁbrinogen 
molecules. Later, if thrombin remains active, more SF is created and forms a ﬁbrin 
gel in which the subunits are cross-linked by FXIII. Plasmin, the most important ﬁ-
brinolytic enzyme, may degrade ﬁbrinogen, SF and cross-linked ﬁbrin. When cross-
linked ﬁbrin is digested, fragments containing dimerized D-domains, including 
D-dimer, are formed. The concentration of D-dimer is primarily a measure of both 
intravascular and extravascular ﬁbrin formation and, to a lesser extent, of ﬁbrin-
olytic activity (Dempﬂe 2002, Dempﬂe 2004).
A large number of test kits based on diﬀerent techniques are commercially available 
for both SF and D-dimer. There is no simple way to compare results from diﬀer-
ent assays. Correlation between diﬀerent SF assays is weak (Dempﬂe et al 1995), as 
their degree of cross-reactivity with ﬁbrin degradation products, varies considerably. 
However, a new monoclonal antibody, IL-43, used in the Iatro SF assay, has been 
found not to recognize cross-linked ﬁbrin degradation products and it therefore has 
a lower correlation with D-dimer (Pearson’s r = 0.26) (Ieko et al 2007). In a study, 
the Iatro SF assay was compared with two latex D-dimer assays; the SF assay iden-
tiﬁed more patients with overt disseminated intravascular coagulation (DIC), and 
exhibited the highest prognostic power concerning mortality (Dempﬂe 2004). One 
possible reason for this might be that D-dimer may stem from intravascular as well 
as extravascular sources, whereas SF appears to be more closely linked to acute in-
travascular ﬁbrin formation. 
Assays for D-dimer, using monoclonal antibodies against conformational epitopes 
of ﬁbrin compounds containing dimerized D-domains, diﬀer concerning speciﬁc-
ity for cross-linked ﬁbrin, with a preference for either high-molecular-weight cross-
linked ﬁbrin derivatives or for low- molecular-weight ﬁbrin degradation products. 
There is no simple linear relationship between diﬀerent assays (Dempﬂe 2003). 
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Therefore, only D-dimer assays tested in appropriate clinical trials should be used to 
rule out VTE. The main source of D-dimer antigen reactivity is not the proteolysis 
of clots but cross-linked ﬁbrin in the circulating blood (Dempﬂe 2005). D-dimer 
enzyme-linked immunosorbent assays (ELISA) have been considered to be the gold 
standard. However, they are cumbersome, labour-intensive and unsuitable for rou-
tine emergency use and have thus been replaced by latex-based systems in the clini-
cal setting.
APC resistance and the FVL mutation
APC resistance was ﬁrst described by Dahlbäck in 1993. He was testing a new 
APTT-based coagulation assay with a ﬁxed amount of added APC. When this test 
was run on plasma from a man suﬀering from recurrent episodes of venous throm-
bosis, prolongation of the clotting time was much shorter than expected. Several of 
the proband’s relatives demonstrated a similar poor in vitro response to APC and 
family studies suggested that the disorder was inherited as an autosomal dominant 
trait with decreased penetrance. The term used for describing this condition was 
“APC resistance”, and the quotient between the two clotting times was called the 
APC ratio. The molecular basis of this phenotype was identiﬁed as the FVL muta-
tion (Bertina et al 1994), a single mutation G?A in position 1691 that converts 
arginine 506 of factor V to glutamine (FV:Q506). FVa:Q506 is 10-fold less sensitive 
to APC-mediated degradation. However, it is slowly cleaved at Arg306 and Arg 679 
(Kalafatis et al 1996), which explains the partial APC sensitivity of individuals with 
FVa:Q506. Thrombi formed in a FVL carrier are more resistant to ﬁbrinolysis due to 
sustained activation of TAFI by APC and subsequent inhibition of ﬁbrinolysis (Ba-
jzar et al 1996), another way the mutation may contribute to thrombosis.
More than 90% of patients with APC resistance are carriers of the FVL (Zöller et 
al 1994) mutation. 
It is the most common thrombophilia among Caucasians and the prevalence of 
heterozygosity in Caucasian populations is reported at 2 - 15 %. The highest preva-
lences are found in northern Europe and the Middle East. Haplotype analyses by 
Zivelin support a single origin for FVL and the mutation is estimated to have arisen 
between 17 000 and 29 000 years ago, i.e. after the evolutionary divergence of Afri-
cans from non-Africans and of Caucasoid from Mongoloid subpopulations towards 
the end of the last glacial period. It has been suggested that the founders of both this 
and the prothrombin gene mutations lived in the Middle East because the current 
prevalences of both mutations are higher in ancient Middle Eastern populations 
than in other white populations (Zivelin et al 1997 and 2006). 
The FVL mutation’s widespread presence among Caucasians suggests that it may 
be a balanced polymorphism with some advantages conferred upon heterozygotes, 
especially in pre-modern times when death from bleeding associated with child-
birth, trauma, or warfare was a signiﬁcant risk and when scurvy was a common 
condition.
The increase in risk of a ﬁrst VTE was found to be 7.9 (95 % conﬁdence interval 
(CI) 4.1-13) in heterozygotes and 91 (95 % CI 26-322) in homozygotes (Bertina 
1997). The presence of other thrombophilic mutations multiplies the risk of VTE. 
21
Back ground
Deﬁciency of protein Z leads to a bleeding tendency in non-carriers but raises the 
risk of VTE in FVL carriers (Kemkes-Matthes et al 2004).
Since 1994, a few other rare FV mutations leading to APC resistance have been 
found: Arg306 to glycine (FV Hong-Kong) or threonine (FV Cambridge) and muta-
tions leading to low FV levels (FV R2 haplotype). Concomitant heterozygous FVL 
mutation in one gene and mutation in the other gene leading to FV deﬁciency is 
called pseudo-homozygous APC resistance and results in an APC ratio in the refer-
ence range for homozygosity of the FVL mutation. This is explained by the fact that 
FV is not only a procoagulant but also an anticoagulant, as it is a cofactor, together 
with protein S, in the degradation of FVIIIa. 
APC resistance can be evaluated in plasma using diﬀerent commercially available 
methods, many of which are derived from the original Coatest APC Resistance test 
method, available since 1993. These tests, classic APC resistance assays, measure the 
classic APC ratio as clotting time in the presence of APC, divided by clotting time 
in the absence of APC. These assays have been shown to have some shortcomings; 
many haemostatic variables can interfere because the test is based on the APTT. 
The assays are susceptible to platelet contamination and to clinical conditions such 
as age; gender; body mass index (BMI); smoking; blood group; APTT; ﬁbrinogen, 
homocysteine, triglyceride and total cholesterol levels; all conditions giving rise to 
high levels of plasma FVIII.
Low classic APC ratios have been found among individuals with the metabolic syn-
drome (Tosetto et al 1997),?during oral contraceptive use and pregnancy (Cumming 
et al 1995, Mathonet et al 1996, Peek et al 1997, Schlit et al 1996, Vasse et al 1994) 
and in individuals with lupus anticoagulants (LA) (Nojima et al 2009). In one study 
a correlation was found between the classic APC ratio and the protein C level (Ma-
heiu et al 2007). The APC ratio is not useful during treatment with heparin or oral 
anticoagulants (OAC). It has also been shown that the APC ratio increases in plasma 
samples with only slightly reduced levels of FII, FVIII and FX (Ronde et al 1994). 
The condition with a classic APC ratio below the lower limit of the reference interval 
in the absence of a FV gene mutation is called acquired APC resistance. Studies have 
shown that there is a correlation between this condition, blood coagulation activa-
tion and subsequent incidences of VTE (de Visser et al 1999). The results from stud-
ies assessing the relationship between acquired APC resistance and the incidence of 
placenta-mediated complications are conﬂicting (Lindqvist et al 2006, Mimuro et al 
1998, Paternoster et al 2002) but a relationship between a low ratio and thrombotic 
lesions in the placenta has been found (Sedano et al 2008).
 
Modiﬁed APC resistance tests are based on pre-dilution (1:4) of the sample plasma 
with FV-deﬁcient plasma prior to analysis, which is then performed according to 
routine. This procedure makes the method much more speciﬁc for alterations in the 
FV molecule, resulting in a very high discrimination of the FV:R 506Q mutation as 
well as the ability to analyse plasma from OAC- and heparin-treated individuals and 
pregnant women (Jorquera et al 1996). The modiﬁed APC resistance test used in the 
research underlying this thesis has been reported to have 100% sensitivity and 100% 
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speciﬁcity for the FVL mutation and distinguishes homozygous from heterozygous 
individuals (Freyburger et al 1997, Gouault-Heilman et al 1996, Hall et al 1998, van 
Oerle et al 1997, Sifontes et al 1997). It cannot, however, be ruled out that analysis 
of plasma from patients with high LA titres and from patients with FV deﬁciency 
may yield misleading results. 
FVL – mutation or polymorphism or what?
 There is an ongoing debate concerning the nomenclature of variants in our genetic 
code.  In biology, mutations (Latin: mutatio=change) are changes in the nucleotide 
sequence of the gebetic material of an organism. Less favourable mutations can be 
reduced in frequency in the gene pool by natural selection, while more beneﬁcial or 
advantageous mutations may accumulate and result in adaptive evolutionary chang-
es. Sometimes the term “mutation” is used to simply indicate “a disease-causing 
change”. However, the fact that the term “mutation” has developed a negative con-
notation, associated with abnormality and terms with intense negative connotations 
such as “monstrosities” or “freaks”, has resulted in the emergence of other terms for 
describing genetic processes. The term polymorphism (Greek: polys morphës=many 
forms) has been proposed to indicate a non-disease-causing change or a change 
found at a frequency of 1% or higher in the population. “Balanced polymorphism” 
is the suggested term for a condition that has advantages for the heterozygote but 
is hazardous for the homozygote. This deﬁnition is not unambiguous. FVL would 
be a mutation in some parts of the world and a polymorphism in others. Neutral 
terms such as “sequence variant alteration” or “allelic variant” have been suggested, 
instead of mutation and polymorphism, in order to prevent this confusion (Condit 
et al 2002).
However, without mutations we would have still been multi-layered microbial mats, 
so the term mutation has been chosen, in this thesis, to deﬁne a single base change.
Other thrombophilias
The prothrombin G20210A mutation, leading to increased prothrombin generation, 
was reported in 1996 (Poort et al 1996). In that study the odds ratio (OR) for throm-
bosis was 2.8 (95% CI 1.4-5.6) in heterozygous carriers. Haplotyping suggests that 
the mutation arose 19 000-31 000 years ago and has the same geographic extent 
as the FVL mutation (Zivelin et al 1998 and 2006). However, prevalences (range 
1.7-6.7) are highest in the Middle East and lowest in northern Europe (Rosendaal et 
al 1998, Zivelin et al 1998). The prevalence of the prothrombin mutation has been 
found to be doubled in FVL carriers, compared with non-carriers, suggesting that 
these mutations originated in the same area (Ehrenforth et al 1998). Concomitance 
of heterozygosity for these two mutations is often called double heterozygosity. A 
survival advantage based on a protective prenatal eﬀect of this genotype, such as 
improved embryonic implantation, has been suggested (Hundsdoerfer et al 2003). 
Another eﬀect can be a decreased bleeding tendency, comparable with the FVL 
mutation’s eﬀect.
AT, protein C and protein S are the most important downregulators of coagula-
tion. Deﬁciencies of these plasma proteins are strong risk factors for VTE. There are 
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several diﬀerent types of genomic abnormalities responsible for these conditions. If 
the mutation leads to a reduction in the amount of circulating protein it is called a 
type 1 or quantitative deﬁciency and if the mutated allele produces a variant protein 
with less activity it is called type II or qualitative deﬁciency. In clinical practice, an 
individual is said to have symptomatic deﬁciency if he or she has a low level and at 
least two relatives with low levels and a history of VTE. The condition is also called 
symptomatic phenotype. The respective prevalences of AT deﬁciency type I and 
type IIc (heparin binding site-related) have been estimated to be 1:4400 and 1:700 
(Tait 1994). The prevalences of protein C deﬁciency type I and protein S deﬁciency 
type I have been estimated at 1:300 (Tait 1995) and 1:300-1:800 (Dykes 2001), 
respectively.
Placenta-mediated complications 
The key feature in IUGR, preeclampsia and often in spontaneous abortion is poor 
placentation, leading to deﬁcient uteroplacental blood ﬂow. This is caused by two 
defects involving the spiral arteries. The ﬁrst is a relative absence of trophoblast inva-
sion of the spiral arterial walls during placentation between gestational weeks 8-18, 
caused by an excessive attack by the maternal inﬂammatory response on the zygote 
(Faas and Schuiling 2001), leading to a relative absence of trophoblast invasion of 
the spiral arterial walls during placentation. The second defect is “acute atherosis”, 
i.e. aggregates of lipid-loaded macrophages, platelets and ﬁbrin-creating placental 
infarction. Increased placental apoptopic or necrotic debris is shed from the syn-
cytial surface of the placenta and reaches the maternal circulation, resulting in en-
dothelial damage and activation of blood coagulation. There are increased levels of 
inﬂammatory cytokines, an increased number of natural killer cells and neutrophil 
activation both in the placenta and in the maternal circulation. These changes are 
compatible with a state of low-grade DIC. The process accelerates when pregnancy 
proceeds, and is more pronounced in pregnancies complicated by placenta-mediated 
complications (Redman and Sargent 2003). 
It is possible that the fetus provokes the mother to compensate for poor placentation 
by increasing her blood pressure (Greer 2001). The maternal response may depend 
on the woman’s genotype and/or phenotype. Women with insulin resistance or oth-
er risk factors for atherosclerosis and women with underlying inﬂammatory condi-
tions may exhibit an exaggerated inﬂammatory response and those with congenital 
thrombophilia may exhibit an exaggerated coagulation response (Greer 2001, Wik-
ström et al 2005). 
The question of whether venous thrombophilia raises the risk of bad obstetric out-
come is under debate. The association between the FVL variant and adverse obstet-
ric outcome is controversial and data in the literature is inconsistent, due to major 
between-study heterogeneity, potential publication bias and sequential testing (Fig-
ure 2). The ﬁve largest case-control studies (GOPEC 2005, de Groot et al 1999, Kim 
et al 2001, Mello et al 2005, O’Shaughnessy et al 1999) and three prospective stud-
ies (Clark et al 2007, Dizon-Townson et al 2005, Lindqvist et al 1999) did not show 
any diﬀerences in the prevalences of gestational hypertension, preeclampsia or severe 
preeclampsia between FVL carriers and controls. Six large studies (Clark 2007, Mc-
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Cowan et al 2003, Dizon-Townson et al 2005, Infante-Rivard et al 2002, Lindqvist 
et al 1999, Verspyck et al 2004) indicated no elevated risk for IUGR. 
Statistical association has been said to be a matter of fact, whereas causation is a 
matter of opinion. Is the evidence extensive enough to claim that a causal associa-
tion has been proven? Rodger and Paidas thoroughly discussed Hill’s ten criteria for 
causation applied to the issue of thrombophilias causing placenta-mediated compli-
cations, concluding that the criteria were not met in this case (Rodger and Paidas 
2007). 
Several candidate markers, including the classic APC ratio and the PAI-1/PAI-2-
ratio, have been proposed as markers for preeclampsia and small for gestational age 
(SGA); the optimal marker has yet to be discovered. Theoretically, markers of activa-
tion of coagulation such as F1+2, SF or D-dimer might be valuable for prediction of 
placenta-mediated complications. 
For eﬀective screening, rapid and reliable diagnostic tests are required that can pre-
dict the forthcoming onset of disease with precision. Doing so in the ﬁrst trimester 
of pregnancy improves the test’s prognostic value signiﬁcantly because this provides 
time for prophylactic strategies to be implemented.
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Figure 2.  Funnel plot showing results from 32 case-control studies concerning preec-
lampsia and the FVL mutation.
Placental abruption
Placental abruption is often unpredictable and a serious condition with an inci-
dence of 1 in 100-200 pregnancies, associated with high perinatal mortality and 
high maternal morbidity and mortality. Known risk factors are direct trauma to the 
uterus, hypertension (both essential and pregnancy-induced), severe fetal growth 
restriction, cigarette smoking, advanced maternal age and multiparity. The process 
begins with uterine vasospasm, followed by relaxation and consequently venous sta-
sis. The arterioles rupture and the placenta separates from the maternal attachment 
by pressure. The clinical signs are frequent small contractions, elevated uterine tone, 
abdominal pain or backache and sometimes vaginal bleeding. Placental bed biopsies 
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after abruption show the same abnormal vascular structures as in preeclampsia, such 
as inﬂammation of the anchoring villi (Dommisse and Tiltman 1992, Eskes 1997), 
and placental abruption can probably be included among the placenta-mediated 
pregnancy complications. The role of thrombophilia as a risk factor for placental 
abruption is controversial (Figure 3). Two prospective studies failed to detect any 
association between FVL carriership and placental abruption (Dizon-Townson et 
al 2005, Lindqvist et al 1999), as did two of the three largest retrospective studies 
(Jääskeläinen et al 2004, Prochazka et al 2003, Prochazka et al 2007).
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Figure 3.  Funnel plot showing results from 8 case-control studies concerning placental 
abruption and the FVL mutation.
Fetal loss
Pregnancy loss is one of the leading women’s health issues; 25% of reproductive-age 
women experience one clinically recognized loss, 5% experience two or more losses 
and about 1 % suﬀer three or more losses (Regan and Cliﬀord 2001). Most (98%) 
pregnancy losses occur before 12-14 weeks’ gestation (Goldstein et al 1994). Ab-
normal karyotype, infections, luteal phase defects and uterine abnormalities are the 
most common ﬁndings in connection with miscarriage; the problem of confounding 
is thus huge. The incidence of stillbirth (fetal loss after 22 gestational weeks) in our 
region is about 6‰. IUGR, lethal anomalies, abnormal karyotype and infections 
are well-known risk factors but about half of stillbirths are unexplained. The rela-
tionship between fetal loss and thrombophilia, including FVL mutation, has been 
questioned. As human fetal nutrition is mainly histiotrophic until at least 10 gesta-
tional weeks and as the maternal intraplacental circulation is not fully established 
until the third month of gestation, it is unlikely that thrombophilia can cause early 
miscarriage due to increased blood coagulation (Burton et al 2002). A population 
of 85 304 neonates (>98% of all newborns in Berlin) was tested for both the FVL 
mutation and the prothrombin mutation, identifying 5 338 heterozygous and 116 
homozygous FVL infants (Hundsdoerfer et al 2003). According to the Hardy-Wein-
berg equation, 91 homozygous infants would have been expected in this population 
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(p=0.08). The diﬀerence indicates no major prenatal loss of fetal homozygous FVL 
carriers but does suggest a tendency toward signiﬁcance in favour of carriership. 
Numerous early case-control studies with varying design assessing the relationship 
between the FVL mutation and recurrent miscarriage, ﬁrst or second trimester mis-
carriage or IUFD have been published; low but statistically signiﬁcant ORs are often 
found. However, the results are controversial and data in the studies are inconsistent, 
due to major between-study heterogeneity, potential publication bias and sequential 
testing. In some studies, the prevalences of FVL were surprisingly low. Numerous 
meta-analyses including these studies have also been published. However, the largest 
studies did not show any association between fetal loss and FVL (Dizon-Townson 
et al 2005, Gris et al 1997, Lindqvist et al 1999, Rai et al 2001, Roqué et al 2004, 
Völzke et al 2003). The largest case-control study found a signiﬁcantly elevated risk 
(OR 4.8, CI 1.8 –12.4) for fetal loss after 22 gestational weeks (Gris et al 1999) 
but the largest cohort studies did not (OR 1.57, CI 0.76-3.25 (Lindqvist et al 1999, 
Tormene et al 1999, Völske et al 2003). 63 homozygous FVL carriers did not suﬀer 
more fetal losses than controls (Pabinger et al 2000).
VTE during pregnancy 
VTE is one of the major causes of morbidity and mortality among women during 
pregnancy and the puerperium (Andersgaard et al 2008). Long-term complications 
such as postthrombotic syndrome and pulmonary hypertension lead to high costs 
for society and major suﬀering for the aﬀected women (The Swedish Council on 
Technology Assessment in Health Care 2002). The growing uterus alters venous 
blood ﬂow in the legs and pelvis and hormonal changes cause decreased resistance 
in the veins, which increases venous stasis. Together, this leads to an increased risk 
of VTE. The incidence of VTE probably increases at least about fourfold when a 
woman becomes pregnant (Heit et al 2005) and incidence related to pregnancy is in-
ﬂuenced by age, smoking, postpartum care, thromboprophylaxis regimens and the 
frequency of caesarean section. The presence of thrombophilias leads to a multifold 
increase in overall risk.
In two large register studies from Scandinavia, the incidence of pregnancy-related 
VTE was found to be 10 -13/10 000. Half of the episodes occurred antepartum 
and the other half postpartum (Jacobsen et al 2008, Lindqvist et al 1999). A meta-
analysis initially selected 63 articles examining the association of FVL with ﬁrst, or 
recurrent, pregnancy-related VTE. They found that the FVL mutation was associat-
ed with a 4.5- (95% CI 1.8-10.9) and 8.6- (95% CI 5.9-12.6) fold increased risk of a 
ﬁrst VTE during pregnancy in cohort and case-control studies, respectively (Biron-
Andreani et al 2006). The risk of VTE is further increased in women with heredity 
for VTE and in pregnancies complicated by preeclampsia, placental abruption or 
operative delivery. Although thromboprophylaxis is given to women with increased 
risk for VTE according to guidelines, this condition is still one of the major causes 
of morbidity and mortality during pregnancy and the puerperium. More reliable 
risk criteria would be of great value, provoking the question of whether prediction by 
markers of coagulation activation such as F1+2, SF or D-dimer might be feasible.
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Aims
The aims of the studies were to improve our knowledge of haemostasis during 
pregnancy and the puerperium and to evaluate the possibility of using of coagu-
lation and ﬁbrinolysis markers to predict venous thromboembolism (VTE) and 
placenta-mediated complications. 
The speci?c aims were:
????? ?????? ???????? ??? ???????????? ??????? ???????????? ???? ????????????? ??????? 
   normal pregnancy and puerperium in non-carriers of the FVL mutation and to 
   determine reference intervals for haemostatic variables (Paper I).
??? ?? ???????????????????????? ????????????????? ????????????????????? ????????? ??????? 
  C (APC) ratio and the total changes in some haemostatic variables during 
   pregnancy (Paper I).
??? ????????????????????????? ????????????????????? ??????? ???????????? ?????? ?????? 
    pregnancy (Paper II). 
??? ?? ????????????? ?????????? ?????? ??? ????????????????????????????????? ?????? 
   (Paper III).
?????????????????????????????????????????????????????????????????????????????? 
   come, such as major blood loss at delivery, prematurity, preeclampsia, eclampsia, 
   IUGR, late miscarriage, intrauterine fetal death (IUFD), placental abruption and 
   neonatal asphyxia and the risk of VTE (Paper III).
??? ?????????????????????????????? ???????????????????????????????????? ?????? 
  (D-dimer) levels in FVL carriers during pregnancy and the puerperium and to 
   compare them with those in non-carriers (Paper IV). 
???????????????????????????????????????????????? ??? ??? ????????????????????????????? 
 placenta-mediated complications or VTE during pregnancy and the 
   puerperium (Paper IV).
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Participants 
Haemostatic variables and global assessment of haemostasis during pregnancy and 
postpartum (Papers I and II)
48 healthy Caucasian women, mean age 29 (range 23-40), 27 nulliparas and 21 
paras, were recruited to the study at their ﬁrst visit to the antenatal care unit. 42 of 
these women completed normal pregnancies and all infants were healthy with nor-
mal birth weights and Apgar scores > 6 at 5 min. No woman had any haemostatic 
complication during pregnancy, delivery or puerperium.  Four women gave birth 
before the 38th week. Five women were excluded as they developed preeclampsia or 
pregnancy-induced hypertension and one woman was excluded because of heterozy-
gosity for the FVL mutation.
 
Prevalence of the FVL mutation, pregnancy outcome and determination of F1+2, SF 
and D-dimer during pregnancy and postpartum in FVL carriers (Papers III and IV)
Healthy Caucasian pregnant women without previous VTE were given written in-
formation about the study concerning hereditary APC resistance at their ﬁrst visit, 
in about the 12th gestational week, at 46 antenatal care centres. The only additional 
criterion for inclusion was that the participants were required to understand the 
Swedish language. 
4 268 and 1 718 women in Gothenburg and Stockholm, respectively, accepted par-
ticipation in the study and were screened for hereditary APC resistance. 483 tested 
positive for the FVL allele with polymerase chain reaction (PCR) technique. 
Another 17 FVL carriers, previously genotyped because of heredity for VTE and 
without previous VTE, were enrolled and added to the carrier group. Every ﬁfth 
woman with modiﬁed APC ratio above the lower reference limit served as a con-
trol (Paper III). The heterozygous FVL carriers, the homozygous FVL carriers, the 
women with double heterozygosity and the controls were equal regarding age, parity, 
BMI, smoking and essential hypertension. There were no diﬀerences between the 
study group and controls regarding mode of delivery or anaesthesia during delivery. 
The follow-up duration after delivery was at least six weeks.
The 500 women with the FVL mutation were followed regarding levels of haemo-
static markers during pregnancy and the puerperium (Paper IV).
Methods 
In Paper I, blood sampling was performed between 8-10 a. m. at gestational weeks 
10-15, 23-25, 32-34 and 38-40, within one week after delivery and eight weeks 
postpartum. Haemoglobin (Hb), haematocrit and platelet count were analysed on 
the same day. Classic APC ratio, modiﬁed APC ratio, ﬁbrinogen, FVIII, protein 
C, free protein S, t-PA, PAI-1, PAI-2, F1+2, SF and D-dimer GOLD were analysed 
later in series.  
In Paper II, Sonoclot analysis was performed at gestational weeks 10-15, 32-34 
and 38-40 and eight weeks postpartum. After taking the ﬁrst 2 ml of whole blood 
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for other analyses, the cuvette was ﬁlled with 0.4 ml whole blood, using a plastic 
syringe, and a Sonoclot signature was performed with a Sonoclot® II analyser within 
1 min The following variables were analysed: sonact time, clot rate, secondary rate, 
peak amplitude, peak time and downward rate.  
In Paper III, blood samples for analysis of modiﬁed APC ratio were taken in gesta-
tional week 17 at the routine ultrasound scan appointment. Women with modiﬁed 
APC ratio <2.0 were genotyped for the FVL mutation. 
In Gothenburg, according to clinical routine in connection with detection of any 
thrombophilia, extended testing was performed, consisting of analysis of prothrom-
bin gene mutation, AT, protein C and free protein S activity. All FVL carriers were 
personally given information about the thrombophilia, including known conse-
quences during pregnancy and other situations, and recommended to use com-
pression stockings. According to local guidelines, low molecular weight heparin 
(LMWH) was recommended as thromboprophylaxis during pregnancy for condi-
tions entailing increased risk of VTE. Women who contracted VTE or superﬁcial 
thrombophlebitis were treated with LMWH in therapeutic doses.
The FVL carriers were compared with controls concerning gestational age at deliv-
ery, gestational hypertension, mild/moderate preeclampsia (MP), severe preeclamp-
sia (SP), syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP), 
eclampsia, IUFD, birth weight deviation, late miscarriage, placental abruption and 
neonatal asphyxia. Furthermore, blood loss at delivery as well as frequency of VTE 
and superﬁcial thrombophlebitis were compared. The number of clinical consulta-
tions on suspicion of VTE was also recorded. 
Women with hemorrhagic disorders, acetylsalicylic acid medication or additional 
thrombophilia (except the prothrombin gene mutation) were excluded after com-
parison of demography, clinical features and incidence of late miscarriage. Further-
more, women treated with LMWH for more than three days during pregnancy as 
well as women with multiple pregnancies and late miscarriages were excluded from 
comparisons of obstetric complications, blood loss and VTE. In addition to these 
exclusions, children with trisomy 18 and 21 and children who died before birth or 
neonatally were excluded when birth weight deviations were compared. 
In Paper IV, blood samples were taken from the FVL carriers between 7.30 and 
10.00 a. m. in gestational weeks 23-25, 32-34, 38-40, one day after delivery and 
four-ﬁve weeks and eight-ten weeks postpartum. Women with multiple pregnancies 
and late miscarriage were excluded. Seven women withdrew from the study. 
F1+2 and D-dimer ELISA were analysed in all 464 women. SF Latex and D-dimer 
Latex were analysed in 56 women who were homozygous FVL carriers or who had 
additional thrombophilias, VTE or placenta-mediated complications (except gesta-
tional hypertension) and in 56 of the heterozygous women with uneventful preg-
nancies matched for age, BMI and parity with the former group. 
The haemostatic marker levels in women with uneventful pregnancies and puerperia 
and in women with additional thrombophilia, homozygosity for FVL, placenta-
mediated complications or VTE at the diﬀerent stages of pregnancy and puerperium 
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were compared. Comparisons were also made between healthy carriers and non-
carriers with uneventful pregnancies. 
Laboratory methods
Blood samples were taken through careful cubital vein venipuncture following a 
20-minute rest. Butterﬂy syringe (23G) and Vacutainer (Venoject®, Terumo, Leu-
ven, Belgium) techniques were used. Blood was collected in tubes containing 0.04 
ml EDTA (0.47 mol/l) for determination of Hb, haematocrit and platelet count, into 
Stabilyte® (Biopool, Umeå, Sweden) tubes for determination of t-PA and into tubes 
containing 0.5 ml trisodium citrate (0.13 mol/l) for the other analyses. The blood 
was centrifuged at 2 000 g for 20 minutes at room temperature within 20 minutes 
of sampling in Paper I and within one hour of sampling in Paper IV. The plasma was 
carefully removed without stirring the buﬀy coat and aliquotted into polystyrene 
tubes. The plasma samples for modiﬁed APC ratio in Paper III were stored at -20ºC 
until analysis, carried out within a week. The plasma samples for the other analyses 
were stored at -70ºC until analysed. In all studies each analysis was run simultane-
ously for all women and the same batches were used. If absorbance was above the top 
standard, the sample was retested after dilution so that the results were read on the 
linear part of the calibration curve.
All analyses were performed by accredited laboratories (ISO 15189). 
Hb, haematocrit, platelet count and AT were analysed according to routine. 
APTT was determined with APTT Coatest (Chromogenix, Mölndal, Sweden). 
The classic APC ratio was determined as the ratio between the time (APTT) with 
and without adding activated protein C (Coatest®, APC Resistance, Chromogenix, 
Mölndal, Sweden). An ACL 300R (Instrumentation Laboratory, Milan, Italy) was 
used for clot time determinations. 
The modiﬁed APC ratio was determined with the method described above
but with the plasma sample pre-diluted 1+4 with lyophilised, stabilised diluent (V-
DEF Plasma, Chromogenix, AB, Mölndal, Sweden) (Paper I) and (COATEST® 
APC™ Resistance V, Chromogenix AB, Mölndal, Sweden) (Paper III). 
FVIII was analysed with an amidolytic assay using the chromogenic substrate 
S-2765 (Coamatic®, Factor VIII, Chromogenix). 
Fibrinogen concentration was analysed using the Clauss method (Fibri- Prest®, Au-
tomate, Diagnostica Stago, Asnières-sur-Seine, France). 
Protein C was determined with a chromogenic assay using the substrate S-2366 
(Coamatic®, Protein C, Chromogenix). 
Free protein S antigen was determined with ELISA (Asserachrom®, Free Protein S, 
Diagnostica Stago). 
The activity of t-PA in plasma was determined by a solid phase enzyme bioimmuno-
assay (Coatest®, BIA t-PA, Chromogenix). 
PAI-1 was determined with ELISA (Coaliza®, PAI-1, Chromogenix). 
PAI-2 was determined with ELISA (Tint Elize®, PAI-2, Biopool). 
F1+2 was analysed with a quantitative ELISA (Enzygnost® F1+2 micro, Dade 
Behring, Marburg, Germany). 
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SF was analysed with an assay based on the ability of SF to stimulate the t-PA-
catalysed conversion of plasminogen to plasmin. The amount of produced plasmin 
was determined with the chromogenic substrate S-2403 (Coatest®, Soluble Fibrin, 
Chromogenix). 
SF Latex was analysed with an automated latex immunoturbidometric assay using a 
monoclonal antibody, IF-43 (LPIA-Iatro, Mitsubishi Kagaku Iatron Inc, Japan). 
D-dimer GOLD was measured as cross-linked ﬁbrin degradation products using an 
ELISA (Dimertest®, GOLD EIA kit, Agen, Acacia Ridge, Australia). 
D-dimer ELISA was analysed with a quantitative ELISA technique (Asserachrome® 
D-Di/ Diagnostica Stago, France). 
D-dimer Latex was analysed with a quantitative latex agglutination assay (STA-
Liatest® D-DI / Diagnostica Stago, France). 
The FVL mutation (Zöller et al 1994) and the prothrombin 20210G>A mutation 
(Poort et al 1996) were detected by PCR coupled with restriction fragment length 
polymorphism analysis (PCR-RFLP). Known wild-type, heterozygous, homozygous 
and blank controls were included in each run. 
Sonoclot analyses were performed using Red Top cuvettes #800±0420 (SIENCO, 
Morison, Colo., USA. The sensitivity was set at 60 and the paper chart speed was 
set at 30 cm/h.
Statistics
Sample size
In order to determine the reference intervals for haemostatic variables (Papers I and 
II) we chose a sample size of 50 women, based on common practice and for practi-
cal reasons. This number provides a good estimate of the mean in order to study 
changes over time. However, these reference intervals are uncertain in the tails of the 
distributions with CI widths, for the limits of the 95% reference intervals, exceeding 
the SD (Papers I and II).
Power analysis was undertaken to determine the required number of participants 
for the study on hereditary APC resistance. The incidences of pregnancy-induced 
hypertension (including preeclampsia), premature delivery and SGA in Sweden are 
reported at 5.0, 6.0 and 2.5 %, respectively (Hanson et Persson 1993). In order to 
achieve 80 % power in ﬁnding a doubled relative risk of the complication with the 
lowest of these incidences in a two-tailed test, 430 cases and 860 controls were re-
quired; 500 cases and 1000 controls were recruited (Paper III).
Descriptive statistics 
The mean, SD, median and range were calculated for each variable and time (Papers 
I, II and III). 
Change over time 
Linear regression was used to determine the change in each variable over time for 
each individual, as plotting the data showed that changes over time existed and 
that they were close to linear. The sample taken eight weeks postpartum was used 
as a non-pregnant baseline value and was set at time zero. The assumption was that 
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random error contribution added up proportionally to time during pregnancy. A 
5% sign test was performed for each variable based on the hypothesis of median 0 
for the change in individuals during pregnancy, with the alternatives increase and 
decrease. (Paper I).
A two-sided paired t-test was used to compare values from samples taken at 10±15 
weeks of gestation with those taken at 32±34 weeks of gestation, and to compare 
samples taken at 32±34 weeks of gestation with those taken at 38±40 weeks of ges-
tation. This test was used to obtain a more precise comparison, as plotting the data 
revealed small diﬀerences between the diﬀerent trimesters. The two-sided paired t-
test was also used to compare values from samples taken at 38±40 weeks of gestation 
with those taken eight weeks postpartum. Multiple testing was taken into consider-
ation by using the Bonferroni correction. (Paper II).
The paired t-test was chosen for comparisons between marker levels at the diﬀerent 
sampling occasions as there was some missing data at the diﬀerent occasions. The 
statistical analyses were performed on logarithmic transformed data, as the variables 
showed a positive skewed distribution. Multiple testing was taken into consideration 
by using the Bonferroni correction. (Paper IV).
Comparison of independent groups 
In Paper III the two-sample t-test was used for comparing demographic and clinical 
features as well as outcome, such as frequency of thromboprophylaxis, birth weight 
deviation and blood loss between groups. Occurrence probability was compared for 
analyses of diﬀerences in smoking and essential hypertension. Blood loss at delivery 
is a positive variable with considerable relative variation and was thus analysed on a 
logarithmic scale.
Comparison of incidences of complications in diﬀerent groups
The relative risks for complications were calculated by cross-tabulation and with 
a 95 % CI. Multiple testing was taken into consideration by using the Bonferroni 
correction. (Paper III).
Correlation between levels of diﬀerent variables
The Spearman rank correlation test, with the signiﬁcance level adjusted for multiple 
testing with a total level of 5%, was used to see if the total changes in the variables 
covaried. The slopes of the linear regression lines from thirty complete series of 
signatures were used as data in these correlation tests, since they were equal to the 
estimated changes over the whole pregnancy period from time zero to 40 weeks of 
gestation. This value is referred to as the total change during pregnancy. A nonpara-
metric test was chosen since normal distribution could not be assumed (Paper I).
The Spearman rank correlation test, with the signiﬁcance level adjusted for multiple 
testing with a total level of 5%, was used to ascertain if any of the Sonoclot variables 
covaried with any of the routine coagulation analyses using all samples (n = 154). A 
nonparametric test was used since normal distribution could not be assumed. (Paper 
II).
Pearson’s correlation test was used to measure the degree of association between 
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the levels of F1+2 and SF and between the levels of SF and D-dimer ELISA at the 
diﬀerent sampling occasions. If r ≥ 0.5 (determination coeﬃcient ≥ 0.25), the as-
sociation is regarded as high. Pearson’s correlation test was also calculated in order 
to characterise the correlation between D-dimer ELISA and D-dimer Latex. In this 
case the same variable is compared using two diﬀerent assays; r ≥ 0.9 is thus regarded 
as acceptable. The calculations were performed on logarithmic transformed data 
(Paper IV).
Funnel plot
Log ORs were plotted against the number of participants in the respective studies. 
The results of large studies are expected to be the closest to real and those of small 
studies are expected to be more widely scattered. Overall, the plots should produce 
an inverted funnel. Asymmetry of the plots proves that a publication bias is pres-
ent. 
Hill’s criteria
The existence of covariance is often interpreted as implying the existence of a causal 
relationship. Two variables (A and B) can be associated for several reasons. Exclud-
ing the possibility that the association can be attributed to chance, it may exist 
because A inﬂuences (or causes) B or because B inﬂuences (or causes) A or because 
both A and B are inﬂuenced by one or more other variables. Hill’s Criteria of Causa-
tion (Hill 1965) provides a valuable instrument with which to evaluate theories and 
explanations proposed in medical science. The criteria are: strength of association, 
consistency of association, temporal relationship, speciﬁcity, biologic plausibility, 
dose-response relationship, coherence, analogy and experimentation.
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Haemostasis in FVL non-carriers during pregnancy and the puerperium 
(Paper I and II)
Haemostatic variables during pregnancy and the puerperium (Paper I)
Hb, haematocrit, APTT and platelet count were within the reference intervals for 
pregnant women.
Compared with non-pregnant individuals, FVIII, ﬁbrinogen, PAI-1 and PAI-2 were 
increased, and free protein S levels were decreased during pregnancy. Eight weeks 
postpartum, 15% of the women still had a free protein S level below the reference 
interval for non-pregnant individuals. There was no change in protein C. t-PA in-
creased but remained within the reference interval. Analyses from the samples taken 
before the women left hospital, at mean 2.4 days postpartum, showed that PAI-1 
had already decreased to the non-pregnant level and that PAI-2 was reduced to 28% 
of the level in the third trimester. Eight weeks postpartum, 11 of the 48 women had 
PAI-1 levels below the lower reference limit for non-pregnant individuals.
F1+2, SF and D-dimer increased during pregnancy. F1+2 and D-dimer were above 
the reference intervals for the majority of patients in the last trimester, while SF 
remained within the reference interval in 80% of the women (Figure 4). All the 
variables except the classic APC ratio and free protein S were within the reference 
intervals for non-pregnant individuals eight weeks postpartum. 
Figure 4.  Mean values for prothrombin fragments 1+2, soluble ﬁbrin and D-dimer dur-
ing pregnancy, within one week after delivery and eight weeks postpartum, respectively. 
Reference ranges apply to non-pregnant individuals. 
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APC ratio during pregnancy and the puerperium (Paper I) 
The classic APC ratios were signiﬁcantly lower during pregnancy than eight weeks 
postpartum, although 92% were above the lower reference limit in the third trimes-
ter. Two women still had a classic ratio below the reference range for non-pregnant 
individuals eight weeks postpartum. All modiﬁed APC ratios during pregnancy were 
above the lower reference limit for non-pregnant women, although linear regression 
showed that there was a small but statistically signiﬁcant decrease over time. 
The Spearman rank correlation test showed no correlation between the total change 
during pregnancy in the classic APC ratio and the changes in FVIII (rs = 0.041), 
ﬁbrinogen (rs = 0.028), protein S (rs = -0.36), F1+2 (rs = 0.12) or SF (rs = -0.032); nor 
between the change in SF and changes in F1+2 (rs = 0.27), ﬁbrinogen (rs = 0.41) or 
D-dimer (rs = 0.35). We found no correlation between SF in the late third trimester 
and the classic APC ratio in the ﬁrst trimester. 
Sonoclot signature during pregnancy and the puerperium 
Sonoclot analysis indicated hypercoagulability during pregnancy, compared to eight 
weeks postpartum. Sonact time and peak time were unchanged during pregnancy 
and shorter during pregnancy than eight weeks postpartum. Clot rate and second-
ary rate were unchanged but higher during pregnancy than eight weeks postpar-
tum. There was no diﬀerence in peak amplitude or downward rate in pregnancy, 
compared to eight weeks postpartum. The signatures were easy to interpret and had 
the same general shape for each patient over time. A Sonoclot signature reﬂecting 
the late third trimester and one reﬂecting eight weeks postpartum have been drawn 
using the mean values of the variables (Figure 5). We found a small but signiﬁcant 
correlation between APTT and sonact time (r = 0.25) and between APTT and clot 
rate (r = -0.25). There was no correlation between platelet count and secondary rate, 
haematocrit or peak amplitude, or between ﬁbrinogen and peak amplitude.
Figure 5  Sonoclot signature during third trimester (left) and eight weeks postpartum 
(right), drawn based on the mean values of the variables
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Prevalence of FVL mutation and of additional thrombophilias (Paper III)
5 986 women were tested for APC resistance. 483 with a modiﬁed ratio <2.0 were 
genotyped for the FVL mutation and tested positive. The prevalence of heterozygous 
FVL mutation was 7.9 %. In Gothenburg the prevalence of homozygous FVL car-
riership was 0.26 %. None of the FVL carriers in Stockholm was found to be ho-
mozygous. In addition to the FVL mutation, ﬁve women (1.4 %) tested positive for 
the heterozygous prothrombin G20210A mutation in Gothenburg. One woman had 
concomitant AT deﬁciency type I and one woman had AT deﬁciency type IIc. No 
deﬁciencies of protein C or protein S were detected. One heterozygous FVL carrier 
with an APC ratio in the reference range for homozygosity was found to have partial 
type 1 quantitative FV deﬁciency (pseudo-homozygous APC resistance). 
FVL carriership during pregnancy and the puerperium (Paper III)
Obstetric outcome 
There was no signiﬁcant diﬀerence regarding placenta-mediated complications. 
The gestational age at delivery was the same. There was no diﬀerence in the birth 
weight deviation in percent. However, the incidences of SGA and large for gesta-
tional age (LGA) were higher in FVL carriers, but the diﬀerence was not signiﬁcant. 
There was one unexplained IUFD among the controls and none among the carriers. 
Furthermore, one intrapartum death occurred in a control with severe preeclampsia. 
One FVL carrier and two controls suﬀered unexplained late miscarriages.
There were no complications, except one premature birth in gestational week 36, 
among the homozygous FVL carriers or women with double heterozygosity.
Blood loss at delivery     
The total blood loss at delivery was lower in the carriers, but the diﬀerence was not 
signiﬁcant. The incidence of blood loss exceeding 1 000 ml was lower among the 
FVL carriers.
Incidence of VTE       
Two heterozygous FVL carriers contracted DVT in the left iliac vein in gestational 
week 28 and 30, respectively. The diagnoses were conﬁrmed by magnetic resonance 
venography and triplex ultrasonography (combination of venous compression, colour 
Doppler and pulsed Doppler ultrasonography), respectively. One heterozygous FVL 
carrier had a PE, diagnosed by s-CT scan, two weeks after vaginal delivery. Two of 
these three carriers had no other risk factors for VTE, while one woman with a DVT 
had heredity for VTE. None of these women had been given thromboprophylaxis. 
Another heterozygous FVL carrier with PE, conﬁrmed by s-CT scan, ﬁve weeks 
postpartum also tested positive for both LA and anticardiolipin antibodies at follow-
up. She was excluded from the study. 
The number of clinical consultations on the women’s own suspicion of VTE was 
fourfold higher among the FVL carriers than among controls. The proportion of 
objective testing, however, was the same in carriers and controls.
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Haemostatic markers in FVL carriers during pregnancy and the puerperium 
(Paper IV)
F1+2, SF and D-dimer in heterozygous FVL carriers with normal pregnancies and 
puerperia
F1+2 increased gradually during pregnancy, but was not higher one day postpartum 
than in the late third trimester. F1+2 was lower eight weeks postpartum than during 
pregnancy. One third of the carriers had F1+2 levels exceeding the reference interval 
for non-pregnant adults eight weeks postpartum. Compared to non-carriers, carri-
ers had signiﬁcantly higher levels of F1+2 eight weeks postpartum, but not during 
pregnancy.
SF Latex was mainly unchanged during pregnancy and at the same level as eight 
weeks postpartum, but there was an increase one day postpartum. Carriers did not 
have signiﬁcantly higher levels of SF Latex during pregnancy or eight weeks postpar-
tum, compared to non-carriers, and the levels were in the same reference intervals as 
those in non-pregnant adults.
D-dimer ELISA increased gradually during pregnancy and was higher one day post-
partum than in the late third trimester. D-dimer ELISA was signiﬁcantly lower eight 
weeks postpartum than during pregnancy. One third of the carriers had a D-dimer 
ELISA level exceeding the reference interval for non-pregnant adults. Carriers had 
signiﬁcantly higher D-dimer Latex levels during both pregnancy and puerperium 
than non-carriers. The correlation coeﬃcients between D-dimer Latex and D-dimer 
ELISA were high during pregnancy and one day postpartum but low four and eight 
weeks postpartum.
The correlations between F1+2 and SF Latex during the second and early third tri-
mester were low but signiﬁcant but they were not signiﬁcant in the late third trimes-
ter, after delivery or postpartum.
The correlations between SF Latex and D-dimer ELISA during pregnancy and one 
day postpartum were high but not signiﬁcant four or eight weeks postpartum.
F1+2, SF and D-dimer in homozygous FVL carriers, carriers with additional throm-
bophilias or with complications during pregnancy or the puerperium
The levels of the markers in homozygous FVL carriers, carriers with additional 
thrombophilias or with complications during pregnancy or the puerperium were in 
the same ranges as in the heterozygous women with normal pregnancies and puer-
peria. The ratio SF Latex /D-dimer ELISA was not higher in women with complica-
tions than in women with uneventful pregnancies or puerperia.
39
Discussion
Discussion
Study design
In Papers I and II, a sample size of 50 women was chosen to determine reference 
intervals for haemostatic variables, based on common practice and for practical 
reasons. Reference intervals are most often used in clinical chemistry to provide a 
standard reference against which to assess substance levels in patients under investi-
gation. The reference interval is simply the estimated range of values that includes a 
certain percentage (most often 95%) of the values among the relevant population. It 
is either estimated directly from observation or from the antilog values of the mean 
±1.96 SD of the logged values (geometric mean), as clinical data are never normally 
distributed. Choosing 50 as a sample size yields a good estimate of the mean in order 
to study changes over time. However, these reference intervals are uncertain in the 
tails of the distributions; the widths of the CI, for the limits of the 95% reference 
intervals, exceed the SD of the observations. Furthermore, it is not advisable to use 
the reference intervals as a basis for decision-making, as it is uncertain whether val-
ues outside them indicate clinical health problems or whether values inside them are 
unassociated with health problems. The more appropriate prediction intervals are 
wider than the reference intervals. 
Eight weeks postpartum was chosen to represent the non-pregnant state. All haemo-
static variables had returned to the reference interval for non-pregnant individuals 
except the classic APC ratio, PAI-1 and free protein S in some women. Perhaps it 
would have been better to wait until after the breast-feeding period to undertake the 
ﬁnal sampling. However, that might have entailed some women moving out of the 
region, some becoming pregnant again and some having started to use hormonal 
contraception, which can also inﬂuence haemostatic variable levels. 
In Papers III and IV, our intention was to investigate the prevalence of the FVL mu-
tation, plasma levels of haemostatic markers and the incidences of placenta-mediated 
complications and VTE. This required a prospective study. In order to ﬁnd about 
500 women with the FVL mutation, we selected a cohort of about 6 000 women. 
With a sample size of about 500 the CI of the limits of the resulting reference inter-
vals are about 0.35 SD, but the above-mentioned caveat concerning clinical applica-
tion of reference intervals must still be taken into consideration. 
In order to decide if the pregnancy was normal or if the criteria for a complication 
were met, it was necessary to scrutinize the medical records. The diagnoses in medi-
cal records are very often inadequate. We thus chose the case-cohort study design 
and selected every ﬁfth non-carrier as a control. This design allows calculation of the 
risk ratio without the need for the rare-disease assumption (Sato 1994).
 The prospective design is not useful in ﬁnding elevated relative risks of rare condi-
tions like placental abruption and IUFD. The absolute risk is more informative and 
most clinicians ﬁnd it more appealing to discuss the chance of an uneventful preg-
nancy than the risk of contracting a rare condition with a patient (Paper III).
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Haemostasis in FVL non-carriers during pregnancy and postpartum
Haemostatic variables during pregnancy and the puerperium (Paper I) 
Haemostatic variables were analysed in order to obtain reference intervals for FVL 
non-carriers. There was a change towards a hypercoagulable state with increased 
concentration of blood coagulation factors and ﬁbrinolysis inhibitors, decreased 
t-PA activity and decreased or unchanged concentration of blood coagulation in-
hibitors, which is in agreement with many other studies concerning haemostasis 
during pregnancy. 
The mean values of FVIII and ﬁbrinogen were almost doubled during the last tri-
mester, compared to the non-pregnant state. Other studies (Hathaway and Bonnar 
1987, Hellgren and Blombäck 1981, Mathonet et al 1996, Schlit et al 1996, Stirling 
et al 1984) have shown a similar increase. The protein C level was within the refer-
ence interval for non-pregnant women and did not change during pregnancy. This 
ﬁnding corresponds to those from other studies (Bremme et al 1992, Faught et al 
1995, Hathaway and Bonnar 1987, Stirling et al 1984). The concentration of free 
protein S dropped early during the ﬁrst trimester and decreased continuously during 
pregnancy, as described previously (Bremme et al 1992, Faught et al 1995, Stirling et 
al 1984). Eight weeks postpartum 15% of the women still had levels below the refer-
ence interval for non-pregnant women, which is in accordance with another study 
(Bremme et al 1992). Thus, the free fraction of protein S does not seem to reach 
the non-pregnant value within eight weeks postpartum, which might be taken into 
consideration when evaluating thrombophilia. This is probably also why a remark-
ably high prevalence of protein S deﬁciency is found in many case-control studies 
of pregnancy complications, both among the cases and controls. Furthermore, some 
functional protein S assays and functional protein C assays yield false low values in 
cases of FVL mutation (Faioni et al 1994, Jennings et al 2000).
The results of studies on ﬁbrinolysis alterations in pregnancy are diﬃcult to inter-
pret, as decreased levels of t-PA and increased levels of PAI-1 would suggest impaired 
ﬁbrinolysis concomitant with increasing levels of D-dimer. Thus, ﬁbrinolysis com-
pensates for increased ﬁbrin formation during pregnancy and the micro-circulation 
in the placenta is maintained during normal pregnancy. 
t-PA activity decreased during pregnancy, as previously described (Ishii et al 1994). 
This is partly an eﬀect of increased production of PAI-1 in the placental endothe-
lium. Other studies show increasing PAI-1 and PAI-2 levels during pregnancy 
(Bremme et al 1992, Dalby Sörensen et al 1995, Estellés et al 1990, Halligan et al 
1994). However, the mean levels of PAI-1 and PAI-2 found in this study were within 
these previously published intervals. PAI-1 and PAI-2 levels normalised rapidly after 
delivery. PAI-2 levels that might have been due to remaining trophoblast were found 
eight weeks postpartum in two patients, although neither patient had any clinical 
symptoms.
Classic and modiﬁed APC ratio during pregnancy and the puerperium (Paper I)
The classic APC test showed decreasing ratios during pregnancy, similar to the de-
velopment reported in other studies (Cumming et al 1995, Mahieu et al 2007, Ma-
thonet et al 1996, Peek et al 1997, Schlit et al 1996, Vasse et al 1994). The modiﬁed 
Paper I and II( )
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APC resistance test showed a minimal, albeit signiﬁcant, decrease during pregnancy. 
However, all the modiﬁed ratios during pregnancy and the puerperium were above 
the reference limit for non-pregnant women. This result agrees well with three other 
studies (Benedetto et al 2002, Cumming et al 1996, Schlit et al 1996). Two women 
had a classic APC ratio below the reference interval for non-pregnant individuals 
eight weeks postpartum. The modiﬁed APC test is consequently more useful in 
order to detect the FVL mutation during pregnancy, during which the classic APC 
test may yield false positive results.  
Our intention was to study the inﬂuence of haemostatic variables on the classic APC 
ratio. We found no explanation for the “acquired” APC resistance, as there was no 
correlation between the total change in the classic APC ratio and the total changes 
in FVIII, ﬁbrinogen or free protein S during pregnancy, in agreement with other 
studies (Mahieu et al 2007, Vasse et al 1994). The results concerning the correla-
tion between the classic APC ratio and FVIII are conﬂicting (Cumming et al 1995, 
Mahieu et al 2007, Mathonnet et al 1996). In an experimental study, in which the 
classic APC ratio was measured in series of pooled normal non-pregnant plasma 
diluted in protein S-deﬁcient plasma, the ratio remained constant when free protein 
S was above 20% (Ronde and Bertina 1994). 
Sonoclot signature during pregnancy and the puerperium (Paper II)
We found the Sonoclot® analyser rapid and simple to handle and the Sonoclot sig-
nature simple to interpret. Compared to the signatures eight weeks postpartum, 
the signatures throughout pregnancy were altered in a manner indicating hyper-
coagulability. We chose to present the 90% ranges for all values during pregnancy, 
as normal distribution could not be assumed, and as we found no changes during 
pregnancy. We recommend that the ranges be used with caution, especially their 
peripheral areas. Very few studies have been performed assessing the correlation 
between Sonoclot variables and routine coagulation analyses, and only rarely has a 
statistically signiﬁcant correlation been found. This could be due to the fact that, as 
in this study, the materials were homogeneous and included patients with normal 
haemostasis. However, Spearman’s rank correlation test showed a low but signiﬁ-
cant correlation between APTT and sonact time and between APTT and clot rate. 
Other studies have shown low or absent correlation between these variables (Ekbäck 
et al 1995, Goldman et al 1993, Schött et al 1995, Steer and Krantz 1993). We found 
no correlation between platelet count and secondary rate, concurring with another 
study (Horlocker and Schroeder 1997). The platelet count provides a quantitative 
but not a qualitative index of platelet status, both of which inﬂuence the second-
ary rate. Furthermore, the secondary rate is inﬂuenced by ﬁbrin formation and po-
lymerisation. We found no correlation between haematocrit and peak amplitude or 
between ﬁbrinogen concentration and peak amplitude, perhaps due to the fact that 
peak amplitude is a measure of maximal viscosity during the coagulation process. 
Lack of correlation between ﬁbrinogen concentration and peak amplitude has been 
reported previously (Goldman et al 1993). 
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Prevalence of the FVL mutation and of additional thrombophilias (Paper III)
The prevalence of FVL carriership was 8.1 %, which is lower than the 11 % preva-
lence previously reported from Malmö in the south of Sweden (Lindqvist et al 1999). 
Women with heredity for VTE might have been more prone to participate and some 
women did not want information concerning an increased risk of contracting a dis-
ease. These circumstances might have led to a volunteer bias leading to both un-
der- or overestimation of the prevalence. The fact that the women with previous 
VTE were not enrolled may have led to a slight underestimation of the prevalence 
(estimated at 0.2 %). 
The prevalence of homozygosity was calculated on the material from Gothenburg 
and found to be 0.26 %; according to Hardy-Weinberg’s equation, a prevalence 
of 0.16 % (95 % CI 0.11-0.41 %) would have been expected. The prevalence of 
heterozygous prothrombin G20210A variant was 1.4 %. Other studies have reported 
a prevalence of 1.7 % in a general population in northern Europe (Rosendahl et al 
1998). The six women with double heterozygosity were not excluded from the study, 
as the same prevalence of the prothrombin G20210A variant is assumed to exist in 
the control group. Three of the 360 FVL carriers in Gothenburg had other addi-
tional thrombophilias. Due to the very low prevalences of these thrombophilias (AT 
deﬁciency type I and type IIc and pseudo-homozygous APC resistance) in the pres-
ent study and in general populations, their presence was assumed to be very low in 
the control group (Simioni et al 2005, Tait et al 1994) and would not, we presumed, 
inﬂuence the results. 
FVL carriership during pregnancy and the puerperium (Paper III)
Obstetric outcome 
The incidences of placenta-mediated complications were low, but concurred with 
data from the Swedish Medical Birth Register (Hanson and Persson 1993).
Cross-tabulation showed no diﬀerence between the FVL carriers and controls re-
garding placenta-mediated complications. This ﬁnding might be due to the fact that 
pathological changes in the placental vessels in the studied conditions are more simi-
lar to pathology in atherosclerotic diseases such as myocardial infarction, ischemic 
stroke and peripheral arterial disease (Redman and Sargent 2003). The FVL variant 
is a thrombophilia entailing increased risk of VTE. The current literature contains 
no solid evidence to support an important relationship between the FVL variant 
and atherosclerotic diseases (Boekholdt and Kramer 2007). However, when recruit-
ment to this study commenced, there was scarce published data either conﬁrming 
or refuting any such relationships. The prevalences of gestational hypertension, MP 
and SP were not higher in FVL carriers than in controls, and were in accordance 
with the ﬁve largest case-control studies (GOPEC 2005, de Groot et al 1999, Kim et 
al 2001, Mello et al 2005, O’Shaughnessy et al 1999) and three prospective studies 
(Clark et al 2007, Dizon-Townson et al 2005, Lindqvist et al 1999). The assumption 
that women with congenital thrombophilia might exhibit an exaggerated coagula-
tion response to endothelial damage could not be conﬁrmed in this study.
We found no signiﬁcant diﬀerence in birth weight deviation between FVL carriers 
and controls, indicating no elevated risk for IUGR, in agreement with other large 
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studies (Clark et al 2007, McCowan et al 2003, Dizon-Townson et al 2005, Infante-
Rivard et al 2002, Lindqvist et al 1999, Verspyck et al 2004). The weight distribu-
tion of the FVL carriers’ neonates had a higher kurtosis than that of the controls’ 
neonates, resulting in more cases of SGA and LGA among the carriers. However, 
these diﬀerences were not signiﬁcant if multiple testing is taken into consideration. 
The mean gestational age at delivery was equal in the two groups, indicating that 
there was no higher rate of conditions requiring induction of delivery or spontaneous 
preterm delivery. If the FVL and the prothrombin G20210A mutations had been as-
sociated with bad obstetric outcome, lower birth weight would have been expected 
in neonates born to the women with homozygous FVL or double heterozygosity.
Adverse outcome such as eclampsia, HELLP syndrome, placental abruption, late 
miscarriage, low Apgar score, IUFD and intrapartum death were rare events. Our 
results did not support the assumption that FVL carriership raises the relative risk 
of these obstetric complications. Some of these outcomes can be assumed to be pre-
vented by good obstetric care and are therefore hard to evaluate related to risk fac-
tors. Furthermore, a prospective study of rare conditions requires an unmanageably 
large number of enrolled patients in order to show signiﬁcant diﬀerences and the 
costs would not be justiﬁable. It is more important to consider the absolute risks.
Two prospective studies (Dizon-Townson et al 2005, Lindqvist et al 1999) and two 
of the three largest retrospective studies (Jääskeläinen et al 2004, Procházka et al 
2003, Procházka et al 2007) failed to detect any association between FVL carrier-
ship and placental abruption. The largest case-control study found a signiﬁcantly 
elevated risk (OR 4.8, CI 1.8 –12.4) for fetal loss after 22 gestational weeks (Gris et 
al 1999) but the largest cohort study did not (OR 1.57, CI 0.76-3.25) (Völske et al 
2003).
The question of whether LMWH lowers the risk of placenta-mediated complications 
in women is under debate. Many authors suggest that women with placenta-medi-
ated complications in previous pregnancies should be given thromboprophylaxis if 
their venous thrombophilia work-up is positive. As placenta-mediated complications 
seem to be associated with atherosclerotic diseases and since LMHW is useful in 
treatment of other arteriosclerotic complications, it would be a pity if prophylaxis is 
withheld from the women without venous thrombophilia. 
Blood loss at delivery 
Estimation of blood loss at delivery is uncertain, but as the same method was used in 
all parturients, we considered a comparison to be appropriate. There was no diﬀer-
ence in blood loss volume at delivery. However, the fact that the number of women 
with blood loss exceeding 1 000 ml was lower among the FVL carriers suggests a 
possible survival advantage of FVL carriership in times when bleeding complica-
tions could not be treated appropriately and scurvy was a common condition. This 
ﬁnding concurs with a previous report (Lindqvist et al 1999) but was not conﬁrmed 
in a more recently published study (Clark et al 2007).
Incidence of VTE 
One weakness of the study is that the risk of VTE in unknown FVL carriers during 
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pregnancy might have been underestimated, due to the non-blinded design. More 
FVL carriers than controls were given thromboprophylaxis and recommendations 
for compression stockings, according to clinical routines, which might have pre-
vented some VTE complications. 
The incidence of superﬁcial thrombophlebitis did not diﬀer between the FVL carri-
ers and controls, in agreement with another study (McColl et al 1998).
The number of clinical consultations on suspicion of VTE was fourfold higher 
among the FVL carriers than among controls, possibly due to heightened anxiety 
resulting from knowledge of the thrombophilia and its risks. The issue of whether 
to screen pregnant women for the FVL mutation is under debate. The patients and 
their relatives may beneﬁt from genotyping but they may also be harmed both psy-
chologically and economically, e.g. by jeopardized health insurance coverage.
Haemostatic markers during pregnancy and the puerperium (Paper I and IV) 
Activation of blood coagulation in vivo can be determined by analysis of F1+2, 
SF and D-dimer. During uncomplicated pregnancy, the increase in SF may reﬂect 
increased ﬁbrin formation, presumably in the uteroplacental unit. D-dimer reﬂects 
both blood coagulation activation and ongoing ﬁbrinolysis. To estimate the degree 
of blood coagulation activation, ﬁbrin formation and ﬁbrin degradation, the ideal 
tests would measure the rate of formation of the actual markers. Instead, the concen-
trations of the markers are used as proxies. These are intermediate products in multi-
step processes and are dependent on both the formation rate and the reaction rate 
of the next step in the reaction chain and elimination from the body. Perhaps this 
is more prominent in the case of SF, which might explain the lower variation in the 
levels of this substance. The importance of increased levels of coagulation activation 
markers is uncertain but increased levels are found in cases of VTE and in patients 
with thrombophilia (Ginsberg et al 1995). Our results were only compared with 
results from studies using the same or very similar assays, as there is no simple way 
of transforming the data. Even if the diﬀerences were signiﬁcant, there was always a 
considerable overlap, in this study as well as in the studies to which we refer.
Haemostatic markers in FVL non-carriers during pregnancy and the puerperium 
(Paper I)
F1+2, SF and D-dimer were used in order to obtain reference intervals for FVL non-
carriers. We found gradual increases of F1+2, and D-dimer ELISA levels, up to those 
found in acute thromboembolic events, as well as higher levels during pregnancy 
than in the non-pregnant state, in agreement with other studies (Bellart et al 1997, 
Bremme et al 1992, Cerneca et al 1997, Comeglio et al 1996, Eichinger et al 1999, 
Francalanci et al 1995, Lindoﬀ et al 1993, Nolan et al 1993, Schambeck et al 2001, 
Schlit et al 1996). 
F1+2, SF and D-dimer in heterozygous FVL carriers with normal pregnancies and 
puerperia (Paper IV)
When blood sampling for Paper IV was completed, the assays for SF and D-dimer 
used in the ﬁrst study were not available. We therefore used other assays, with other 
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reference intervals, in comparisons of SF and D-dimer in carriers and non-carriers. 
F1+2 and D-dimer ELISA levels in the carriers increased gradually during pregnancy 
and were signiﬁcantly lower eight weeks postpartum than during pregnancy. These 
results concur with the only previously reported longitudinal study of D-dimer in 11 
carriers (Eichinger et al 1999). There were no major alterations in the SF Latex levels 
during pregnancy, in agreement with a cross-sectional study of SF in non-genotyped 
women, in which levels in most of the women were in the interval for non-pregnant 
women (Onishi et al 2007). No other study has been published concerning SF levels 
in normal pregnancy in FVL carriers. The low-grade DIC occurring in normal preg-
nancy does not result in increased SF levels, in contrast to fulminant DIC (Dempﬂe 
et al 2004).
Both SF and D-dimer ELISA were signiﬁcantly higher the day after delivery than in 
the late third trimester, indicating more pronounced activation of haemostasis and 
ﬁbrinolysis in connection with delivery. As in other studies (Cerneca et al 1997, Re-
ber et al 1998) this was not the case for F1+2, which may be an eﬀect of the shorter 
plasma half-life of F1+2. The plasma half-life of F1+2 is reported at 90 min and that 
of SF and D-dimer in plasma is reported at 5-6 hrs and 8 hrs, respectively (Bauer 
2006, Nieuwenhuisen 1993). However, another plausible explanation is that F1+2 
molecules, which remain attached to the phospholipids on the surface of the plate-
lets, escape detection, as our assay was performed on platelet-poor plasma (Cadroy 
et al 1993).
A high percentage of the women still had levels of F1+2 and D-dimer ELISA above 
the reference interval eight weeks postpartum. This is probably because carriers have 
a higher grade of coagulation activation than non-carriers, but also perhaps because 
eight weeks postpartum is not representative for the non-pregnant state and because 
the limits of the reference intervals are uncertain. 
Comparisons between carriers and non-carriers in the non-pregnant state revealed 
small but signiﬁcant diﬀerences in the levels of F1+2 and D-dimer, although the 
overlap was substantial (Leroy-Matheron et al 1996, Martinelli et al 1996, Simioni 
et al 1996, Zöller et al 1996).
Our study showed that women carrying the FVL mutation had higher levels of 
F1+2 than non-carriers eight weeks postpartum, but not during pregnancy. This was 
also found in two other longitudinal studies (Eichinger et al 1999, Schambeck et al 
2001). 
We found no diﬀerence between SF Latex levels in carriers and non-carriers during 
pregnancy or eight weeks postpartum, perhaps because SF Latex is an intermediate 
product and the turnover is high.
Compared to women not carrying the FVL allele, carriers had higher levels of D-
dimer Latex both during pregnancy and eight weeks postpartum, in concordance 
with another study (using D-dimer ELISA) (Eichinger et al 1999). We found a high 
correlation between the D-dimer assays during pregnancy and one day postpartum. 
The correlation coeﬃcients were on the same levels as in another study (Dempﬂe 
2001).  The low correlation postpartum between D-dimer Latex and D-dimer ELI-
SA can be explained by the low levels found with the respective assays at that time. 
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Correlation between markers (Papers I and IV)
The correlation between F1+2 and SF was low or absent. This can be explained by 
the fact that the level of F1+2 is a measure of thrombin generation. The formed 
thrombin is partly inhibited (AT, ?2-macroglobulin, and ?1antitrypsin). SF is a mea-
sure of ﬁbrin products produced by the remaining thrombin.
In Paper I there was no correlation between the total change in SF and D-dimer 
Gold. In Paper IV the correlation between SF Latex and D-dimer ELISA was high 
during pregnancy but absent four and eight weeks postpartum. These conﬂicting 
results can be explained by the fact that diﬀerent assays for SF and D-dimer were 
used in these two studies. Perhaps the two assays in Paper I had a lower degree of 
cross-reactivity than those in Paper IV. The SF assay is a global indicator of throm-
bin action on ﬁbrinogen and is based on an antibody detecting epitopes on ﬁbrin 
monomers, ﬁbrin polymers and FXIIIa-induced cross-linked ﬁbrin derivatives; it is 
not, however, intended to detect plasmin-degraded SF products. The D-dimer assay 
is based on an antibody detecting epitopes on the D-D domain in ﬁbrin compounds 
such as D-dimer, plasmin-degraded SF products and, above all, FXIIIa-induced 
cross-linked ﬁbrin derivatives. A positive correlation between SF and D-dimer could 
be due to the fact that they detect the same products. The low correlation between 
this SF assay and D-dimer ELISA (r=0.26) was taken as proof that this antibody, 
which detects SF, does not recognize cross-linked ﬁbrin degradation products (Ieko 
et al 2007, Soe et al 1996). However in another study, Spearman’s rho was 0.75 be-
tween the SF assay, used in this study, and a D-dimer assay (Dempﬂe et al 2001).
F1+2, SF and D-dimer in homozygous FVL carriers and carriers with additional 
thrombophilias (Paper IV) 
The homozygous FVL carriers and carriers with additional thrombophilia had 
markers in the same intervals as the heterozygous carriers with normal pregnan-
cies and puerperia. Only one study is reported concerning markers in non-pregnant 
individuals who were homozygous for FVL or who had additional thrombophilia; 
their mean level of F1+2 was in the lower part of the reference interval (Harbrecht 
et al 1998).
In Paper IV, log SF Latex was plotted against log D-dimer ELISA in order to prove 
the theory that women with placenta-mediated complications or VTE might have 
an imbalance between ﬁbrin formation and ﬁbrinolysis. The plots for women with 
complicated pregnancies were scattered, without any discernible pattern, among the 
plots for matched women without complications. 
If the balance had shifted towards increased ﬁbrin formation or decreased ﬁbrinoly-
sis the plot for the women with complications would have been scattered above the 
regression line.
F1+2, SF and D-dimer in FVL carriers with pregnancy-mediated complications dur-
ing pregnancy and the puerperium (Paper IV)  
There were no diﬀerences in marker levels in women with normal pregnancies or in 
women with pregnancy-mediated complications, either before or after onset. Previ-
ous studies have shown signiﬁcantly higher levels of F1+2 and D-dimer in non-
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genotyped women with SP, early SGA or placental abruption at the time of diagnosis 
than in women with normal pregnancies (Belo et al 2002, Francalanci et al 1995, 
Freeman et al 2008, Nolan et al 1993, Schjetlein et al 1997, Sucak et al 2006). One 
study found no diﬀerence between SF levels in non-carriers with SP and women 
with normal pregnancies (Schjetlein et al 1997), while another study found higher 
levels in the former group (Östlund et al 1998). However, even when diﬀerences 
were signiﬁcant in these studies, there were always substantial overlaps between the 
levels in women with normal pregnancies and in those with placenta-mediated com-
plications. Furthermore, the tests were performed in women already diagnosed with 
the respective complication.
The results of this study may be explained by the fact that the DIC was low-grade. 
Studies have shown increased marker levels in manifest DIC (Dempﬂe et al 2004, 
Kontny et al 1999).
F1+2, SF and D-dimer in FVL carriers with VTE during pregnancy and the puerpe-
rium (Paper IV)  
The women who contracted VTE had markers at the same levels as those without 
complications. In another study, D-dimer was analysed every two to three weeks 
during pregnancy in women with increased risk of thrombosis. They were subdi-
vided into a low-risk, a high-risk and a thrombosis group. No diﬀerences were found 
between the low-risk and high-risk groups but levels were higher in women with 
VTE in the current pregnancy (Bombeli et al 2001).
48
49
Conclusions
conclusions
During normal pregnancy in women who do not carry the FVL mutation, the levels 
of FVIII, ﬁbrinogen, PAI-1 and PAI-2, Fl+2, SF and D-dimer increased and the free 
protein S levels and t-PA activity decreased as pregnancy progressed. There was no 
change in protein C. These results may serve as a reference database, useful for evalu-
ation of haemostasis disorders during pregnancy (Paper I).
Sonoclot analysis indicated a state of hypercoagulability during pregnancy. We 
found the Sonoclot® analyser simple to handle and the signatures easy to interpret. 
The same intervals for the Sonoclot variables can be used throughout pregnancy 
(Paper II).
The prevalence of FVL carriership was 8.1 % (Paper III).
Carriership of the FVL mutation did not inﬂuence gestational age at delivery, the in-
cidence of gestational hypertension or preeclampsia or intrauterine growth. Adverse 
outcomes such as HELLP syndrome, neonatal asphyxia, eclampsia, placental abrup-
tion, late miscarriage, IUFD and intrapartum death were rare events. The incidence 
of blood loss at delivery exceeding 1000 ml was signiﬁcantly lower in the carriers. 
There were three VTEs among FVL carriers and none among the controls. Throm-
boprophylaxis may have inﬂuenced the prevalence of VTE. Genotyping for the FVL 
allele in healthy pregnant women without heredity for VTE is doubtful, nor can 
genotyping be justiﬁed in women with obstetric complications (Paper III).
If a test is to serve as a clinically useful predictor, the overlap between levels in 
healthy and sick individuals should be minor. The results of our study do not sup-
port the assumption that F1+2, SF and D-dimer are useful in prediction of placenta-
mediated complications or VTE in FVL carriers (Paper IV). 
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sammanfattning
Bakgrund
Under graviditet förändras hemostasen i riktning mot hyperkoagulab??itet. Detta 
medför att blödningsrisken vid förlossning minskar, men medför också en ökad risk 
att insjukna i djup venös trombos eller lungemboli, det vill säga i venös tromboem-
bolism (VTE). Vid ärftlig resistens mot aktiverat protein C (APC), som beror på 
en mutation (FVL) i genen för faktor V, ökar denna risk ytterligare. Denna trom-
boﬁli upptäcktes och beskrevs 1993 och är vanligt förekommande bland kaukasier. 
Den kan påvisas genom att beräkna kvoten av APTT med och utan tillsats av APC 
(klassisk APC kvot). Genom att tillsätta FV????????????? kan analysresultatet göras 
oberoende av koncentrationen av övriga koagulationsfaktorer (modiﬁerad APC 
kvot). Den kan också fastställas genom genotypning med polymeraskedjereaktion.
Under graviditet och förlossning kan stora blödningar uppstå, dels beroende på 
komplikationer såsom placentaavlossning, förlossningsskador eller uterusatoni, men 
också beroende på akuta hemostasrubbningar såsom disseminerad intravasal koagu-
lation (DIC) eller trombocytopeni. För att kunna normalisera hemostasen, genom 
att kirurgiskt åtgärda blödningar eller korrigera blodkoagulationen, krävs snabba 
och säkra analysmetoder. Medan konventionella laboratorieanalyser är tidskrävande 
ger Sonoclotanalys inom femton minuter en uppskattning av de olika stegen i he-
mostasen. Dock saknas erfarenhet av och referensintervall för Sonoclotvariabler vid 
graviditet.
Vid placentamedierade komplikationer som preeklampsi, intrauterin tillväxthämn-
ing, placentaavlossning, vissa missfall och intrauterin fosterdöd ses trombotiska 
förändringar i moderkakan. Studier har visat motsägande resultat angående sam-
bandet mellan FVL och dessa komplikationer. 
Vid aktivering av hemostasen ökar koncentrationen av markörer för aktivering av 
blodkoagulation och ﬁbrinolys. Att analysera dessa har visat sig värdefullt vid di-
agnostik av DIC och VTE men kunskap saknas om huruvida höjda nivåer kan 
förebåda placentamedierade komplikationer eller VTE. 
Frågeställningar 
Hur stor är prevalensen av APC resistens i våra geograﬁska områden (Göteborg och 
Stockholm)? 
Kan modiﬁerad APC kvot användas under graviditet för att påvisa bärarskap av 
FVL?
Är Sonoclotanalysen användbar som en snabb bed-side metod för att identiﬁera he-
mostasrubbningar?  
Påverkas incidensen av tromboemboliska eller placentamedierade komplikationer av 
bärarskap av FVL?  
Är koagulationen mer aktiverad under graviditet hos bärare av FVL än hos icke-
bärare? 
Kan man genom att mäta markörer för aktivering av koagulation och ﬁbrinolys 
bedöma risken för tromboemboliska eller placentamedierade komplikationer, för att 
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underlätta ställningstagande till profylaktisk behandling? 
Metodik 
Hemostasvariabler mättes hos friska kvinnor med normal graviditet, vilka var icke-
bärare av FVL-mutationen. 48 kvinnor provtogs sammanlagt fyra gånger under 
graviditeten, inom en vecka efter förlossning samt åtta veckor efter förlossning. Föl-
jande analyser utfördes: klassisk och modiﬁerad APC kvot, markörer för aktivering 
av koagulation och ﬁbrinolys (protrombinfragment 1+2 (F1+2), lösligt ﬁbrin (SF) 
och D-dimer) samt faktor VIII, ﬁbrinogen, protein C, protein S, plasminaktivator 
inhibitorer 1 och 2 (PAI-1, PAI-2) och vävnadsplasminaktivator (t-PA) (Studie I).
Sonoclotanalys utfördes på samma kvinnor som i första studien, tre gånger under 
graviditet samt åtta veckor efter förlossning, för att få en totalbild av koagulationen 
under graviditet och puerperium (Studie II).
5 986 gravida kvinnor i Stockholm och Göteborg provtogs för bärarskap av FVL. 
500 bärare följdes under graviditet och puerperium. Var femte icke-bärare användes 
som kontroll. Bärare jämfördes med kontroller avseende incidens av placentamedi-
erade komplikationer och VTE (Studie III).
Bärare av FVL provtogs sammanlagt tre gånger under graviditeten och tre gånger 
efter förlossning för analys av F1+2, SF och D-dimer. Nivåerna av dessa markörer 
hos bärarna med komplikationsfri graviditet jämfördes med nivåerna hos dem som 
hade komplikationer. Dessutom studerades förändringar över tid under graviditet 
och efter förlossning. Jämförelse gjordes även mellan bärare och icke-bärare (Studie 
IV).
Resultat
Klassisk APC kvot visar på APC resistens hos icke-bärare i sådan utsträckning att 
metoden inte kan användas för bestämning av hereditär APC resistens under gra-
viditet. Modiﬁerad APC kvot låg dock över referensnivån under hela graviditeten. 
Ökning av F1+2, SF och D-dimer indikerade aktivering av koagulationen under 
normal graviditet. Faktor VIII, ﬁbrinogen, PAI-1 och PAI-2 ökade, protein S och 
t-PA minskade medan protein C var oförändrat (Studie I).
Sonoclotanalysen var lätt att utföra och tolka. Sonoclotanalys indikerade hyper-
koagulabilitet under graviditet (Studie II).
Prevalensen av heterozygot and homozygot FVL-bärarskap var 7,9 resp. 0,26 %. 
Det var ingen skillnad i incidenser av graviditetshypertoni, lätt och svår preeklamp-
si, eklampsi, placentaavlossning, intrauterin fosterdöd, oförklarligt missfall eller av-
vikelse i födelsevikt mellan bärare och icke-bärare. Bärare hade mer sällan blodför-
lust överstigande 1000 ml vid förlossning. Bärare hade troligen ökad risk för VTE 
(Studie III).
F1+2 och D-dimer steg successivt under graviditeten men SF låg inom referensom-
rådet för icke- gravida. De kvinnor som utvecklade komplikationer, var homozygota 
för FVL eller hade annan tromboﬁli utöver FVL hade ej högre markörnivåer än 
heterozygota kvinnor utan komplikationer. SF och D-dimer var positivt korrelerade 
under graviditet men ej åtta veckor efter förlossning (Studie IV).
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Slutsatser
Hemostasen är aktiverad under graviditet.
Modiﬁerad APC kvot kan användas för att diagnostisera FVL under graviditet.
Samma intervall för Sonoclotvariabler kan användas under hela graviditeten.
Bärare av FVL har troligen högre incidens av VTE men ej av placentamedierade 
komplikationer.
F1+2, SF eller D-dimer kan ej användas för att förutsäga tromboemboliska eller 
placentamedierade komplikationer.
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